Schechter Investment Advisors, LLC Genmab A/S Transaction History

Schechter Investment Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$26.43 - $32.77 $94,513 - $117,185	3,576 Added 46.36%	11,289 $337,000
Q4 2023 Jan 17, 2024	SELL	$27.94 - $35.44 $167,472 - $212,427	-5,994 Reduced 43.73%	7,713 $245,000
Q3 2023 Nov 06, 2023	BUY	$35.27 - $42.24 $228,055 - $273,123	6,466 Added 89.3%	13,707 $483,000
Q2 2023 Jul 26, 2023	BUY	$37.4 - $42.94 $3,515 - $4,036	94 Added 1.32%	7,241 $275,000
Q1 2023 Apr 28, 2023	SELL	$34.88 - $43.22 $2,860 - $3,544	-82 Reduced 1.13%	7,147 $269,000
Q4 2022 Feb 13, 2023	SELL	$33.8 - $47.06 $31,670 - $44,095	-937 Reduced 11.47%	7,229 $306,000
Q3 2022 Nov 04, 2022	BUY	$31.52 - $373.61 $43,529 - $515,955	1,381 Added 20.35%	8,166 $262,000
Q2 2022 Nov 03, 2022	BUY	$26.83 - $38.57 $182,041 - $261,697	6,785 New	6,785 $220,000
Q1 2022 Nov 18, 2022	SELL	$30.95 - $39.68 $15,691 - $20,117	-507 Reduced 6.21%	7,659 $277,000
Q4 2021 Dec 27, 2022	BUY	$35.87 - $47.12 $1,327 - $1,743	37 Added 0.45%	8,203 $324,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Schechter Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Schechter Investment Advisors, LLC with notifications on news.